Who is sponsoring NCT03054155?

NCT03054155 is sponsored by Wayne State University.

What drugs are being tested in NCT03054155?

Interventions in NCT03054155: Alexandrite Laser.

What condition does NCT03054155 study?

NCT03054155 studies Hidradenitis Suppurativa.

Is NCT03054155 still recruiting?

NCT03054155 is currently completed. Last updated 16 May 2023.

Last reviewed 2023-05-16 · How we verify

NCT03054155

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser

Completed NA Last updated 16 May 2023

What this trial tests

NA trial testing Alexandrite Laser in Hidradenitis Suppurativa in 30 participants. Completed in 31 October 2022.

Timeline

11 May 2017

Primary endpoint
1 September 2022

31 October 2022

Quick facts

Lead sponsor	Wayne State University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	11 May 2017
Primary completion	1 September 2022
Estimated completion	31 October 2022
Sites	1 location across United States

Drugs / interventions tested

Alexandrite Laser

Conditions studied

Hidradenitis Suppurativa — all drugs for Hidradenitis Suppurativa →

Sponsor

Wayne State University

Who can join

Adults 18 to 65, any sex, with Hidradenitis Suppurativa. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with bilateral hidradenitis in the axilla, groin and/or inframammary will be treated on one side with the Alexandrite hair removal laser. The other side will serve as the control.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Hidradenitis Suppurativa: Where We Are and Where We Are Going.
Scala E, Cacciapuoti S, Garzorz-Stark N, Megna M, et al · · 2021 · cited 85× · PMID 34440863 · DOI 10.3390/cells10082094
New perspectives on the treatment of hidradenitis suppurativa.
Amat-Samaranch V, Agut-Busquet E, Vilarrasa E, Puig L. · · 2021 · cited 47× · PMID 34840709 · DOI 10.1177/20406223211055920
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa-Part II: Procedural and Wound Care Therapies.
Fragoso NM, Masson R, Gillenwater TJ, Shi VY, et al · · 2023 · cited 3× · PMID 37402030 · DOI 10.1007/s13555-023-00957-5

Verify or expand the search:

Other recruiting trials for Hidradenitis Suppurativa

Currently open trials in the same condition.

NCT07244263 — A Study of Zasocitinib in Adults With Hidradenitis Suppurativa · Phase 2 · recruiting
NCT07225569 — A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Sup · Phase 2 · recruiting
NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose · recruiting
NCT07282015 — Real-world Secukinumab Outcomes in Canadian HS Patients · recruiting
NCT07228390 — A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps · Phase 2 · recruiting

Other Wayne State University trials

Trials by the same sponsor.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT07123467 — Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder · Phase 3 · recruiting
NCT07222306 — Cannabis, Neuroinflammation, and Suicidal Ideation: A Supplemental Brain Imaging Study · enrolling by invitation
NCT05684978 — Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus · Phase 4 · terminated
NCT06381180 — Warrior CARE: Cannabis Behavioral Health · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03054155 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wayne State University
Last refreshed: 16 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03054155.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing